Clozic (ICI 55897)
(Synonyms: 氯丁扎利,ICI 55897; Clobuzarit) 目录号 : GC31931
Clozic (ICI 55897) 是一种潜在的抗关节炎剂。
Cas No.:22494-47-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Clozic is a potential anti-arthritic agent.
Clozic is a potential anti-arthritic agent. Concentrations of Clozic greater than 50 μM cause a dose-dependent decrease in the amount of matrix protein synthesized by RHMC cell cultures. Inhibition of RHMC cell culture growth by Clozic occurs in a dose-dependent manner. The anti-proliferative effect of Clozic on RHMC cell growth is reversible. Lactate dehydrogenase (LDH) levels in media taken from RHMC cell cultures exposed to 500 μM Clozic for 3 days do not significantly differ from LDH levels in control cell culture media[1].
[1]. Foster SJ, et al. Anti-proliferative properties of Clozic, a disease-modifying anti-arthritic agent. Biochem Pharmacol. 1983 Feb 1;32(3):461-7.
Cell experiment: | Approximately 3×104 to 5×104 cells/mL medium are seeded into 24-well plates and incubated at 37°C in a humidified atmosphere of 95% air/5% CO2. Medium is replaced with fresh medium containing 20% foetal calf serum and methanol or Clozic under investigation. Cell numbers are determined in replicate wells on various days during culture growth[1]. |
References: [1]. Foster SJ, et al. Anti-proliferative properties of Clozic, a disease-modifying anti-arthritic agent. Biochem Pharmacol. 1983 Feb 1;32(3):461-7. | |
| Cas No. | 22494-47-9 | SDF | |
| 别名 | 氯丁扎利,ICI 55897; Clobuzarit | ||
| Canonical SMILES | CC(C)(OCC1=CC=C(C2=CC=C(Cl)C=C2)C=C1)C(O)=O | ||
| 分子式 | C17H17ClO3 | 分子量 | 304.77 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2812 mL | 16.4058 mL | 32.8116 mL |
| 5 mM | 0.6562 mL | 3.2812 mL | 6.5623 mL |
| 10 mM | 0.3281 mL | 1.6406 mL | 3.2812 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet